Klin Farmakol Farm. 2013;27(2):85-88

Pharmacology of golimumab and its use in treating patients with rheumatoid arthritis

David Suchý
Oddělení klinické farmakologie FN Plzeň

The introduction of tumor necrosis factor-α (TNF-α) inhibitors represented a significant progress in the management of rheumatoid arthritis

(RA) and other chronic inflammatory diseases. Golimumab a novel anti-TNF-α monoclonal antibody, has demonstrated significant

efficacy in randomized, double-blind, placebo-controlled phase III trials in the treatment of RA, psoriatic arthritis (PsA), and ankylosing

spondylitis (AS) when administered subcutaneously once every four weeks. This review summarizes the development of golimumab, its

pharmacokinetic properties and clinical evidence achieved with golimumab in treatment of patients with rheumatoid arthritis.

Keywords: golimumab, TNF-α inhibitors, rheumatoid arthritis, safety

Published: July 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Suchý D. Pharmacology of golimumab and its use in treating patients with rheumatoid arthritis. Klin Farmakol Farm. 2013;27(2):85-88.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kay J, Rahman MU. Golimumab: A novel human anti-TNF ? monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Core Evidence 2009; 4: 159-170. Go to original source... Go to PubMed...
    2. Shealy D, Cai A, Nesspor T, et al. Characterization of golimumab (CNTO 148), a novel monoclonal antibody specific for human TNF? [abstract]. Ann Rheumatic Dis. 2007; 66: 151.
    3. Šenolt L. Golimumab. Remedia 2010; 20: 164-171. Go to original source...
    4. Němec P. Golimumab. Farmakoterapie 2010; 6(Suppl): 11-18.
    5. Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007; 47: 383-396. Go to original source... Go to PubMed...
    6. Oldfield V, Plosker GL. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. BioDrugs 2009; 23: 125-135. Go to original source... Go to PubMed...
    7. Visvanathan S, Wagner C, Rojas J, et al. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. J Rheumatol 2009; 36: 1371-1379. Go to original source... Go to PubMed...
    8. Shealy D, Cai A, Staguet K. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor ?. Mabs. 2010; 2(4): 428-439. Go to original source... Go to PubMed...
    9. Fleischmann R. The efficacy and safety of golimumab in the treatment of arthritis. Expert Opin Biol Ther 2010; 10: 1031-1143. Go to original source... Go to PubMed...
    10. Emery P, Fleischmann R, van der Heijde D, et al. Golimumab and Radiographic Progression in Rheumatoid Arthritis: Results of GO-BEFORE and GO-FORWARD Studies. Arthritis Rheum 2009; 10(Suppl): 640.
    11. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68: 789-796. Go to original source... Go to PubMed...
    12. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374: 210-221. Go to original source... Go to PubMed...
    13. Smolen JS, Kay J, Doyle MK, et al. Golimumab in Rheumatoid Arthritis Patients Previously Treated with Anti-TNFa Agents (GO-AFTER Study): Week 52 Results. Arthritis Rheum 2009; 10(Suppl): 1669.
    14. Kay J, Fleischmann RM, Keystone EC, et al. Safety of Golimumab, a New Human Anti-TNFalpha Antibody, in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: An Analysis of Pooled Data From Randomized, Double-Blind, Placebo-Controlled Studies. Arthritis Rheum 2009; 10(Suppl): 295.
    15. Combe B, Dasgupta B, Low I, et al. Efficacy and Safety of Golimumab As Add-On Therapy to Disease-Modifying Antirheumatic Drugs. Arthritis Rheum. 2012; 10(Abstract supplement): S205.
    16. Mok C, Kwan Ch, Chan H, et al. Retention Rate of the Anti-TNF Biologics in the Treatment of Rheumatic Diseases and Predictive Factors for Drug Withdrawal: Data From the Hong Kong Biologics Registry. Arthritis Rheum. 2012; 10(Abstract supplement): S169.
    17. Khalil H, Tahami A. Golimumab Drug Utilization Patterns in Canada-Higher Retention Rate in GolimumabTreated Rheumatoid Arthritis Patients Compared to Etanercept and Adalimumab. 2012; 10 (Abstract supplement): 497.
    18. Zeman J. Certolizumab a léčba revmatoidní artritidy.Klin farmako. farm 2011; 25(2): 76-78.
    19. Strojil J, Ciferská H. Certolizumab pegol. Klin Farmakol Farm 2010; 24(3): 155-160.

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.